1415730-99-2

Basic information

• Product Name: 8-(3-phenyl[1,2,4]oxadiazol-5-yl)-1-oxa-2,8-diazaspiro[4.5]-dec-2-ene-3-carboxylic acid (2,5-difluoro-4-methylsulfanylphenyl)amide
• Synonyms: 8-(3-phenyl[1,2,4]oxadiazol-5-yl)-1-oxa-2,8-diazaspiro[4.5]-dec-2-ene-3-carboxylic acid (2,5-difluoro-4-methylsulfanylphenyl)amide
• CAS NO: 1415730-99-2
• Molecular Weight: 485.514
• Mol File: 1415730-99-2.mol

Chemical Properties

• CAS DataBase Reference: 8-(3-phenyl[1,2,4]oxadiazol-5-yl)-1-oxa-2,8-diazaspiro[4.5]-dec-2-ene-3-carboxylic acid (2,5-difluoro-4-methylsulfanylphenyl)amide(CAS DataBase Reference)
• NIST Chemistry Reference: 8-(3-phenyl[1,2,4]oxadiazol-5-yl)-1-oxa-2,8-diazaspiro[4.5]-dec-2-ene-3-carboxylic acid (2,5-difluoro-4-methylsulfanylphenyl)amide(1415730-99-2)
• EPA Substance Registry System: 8-(3-phenyl[1,2,4]oxadiazol-5-yl)-1-oxa-2,8-diazaspiro[4.5]-dec-2-ene-3-carboxylic acid (2,5-difluoro-4-methylsulfanylphenyl)amide(1415730-99-2)

Safety Data

• Hazardous Substances Data: 1415730-99-2(Hazardous Substances Data)

Upstream product

• 155906-13-1 2,5-difluoro-4-iodophenylamine 
• 112279-60-4 4-bromo-2,5-difluoroaniline 
• 827-44-1 5-chloro-3-phenyl-1,2,4-oxadiazole 

Downstream Products

• 1415731-00-8 C₂₃H₂₁F₂N₅O₄S 

Relevant articles and documents

Identification of new potent GPR119 agonists by combining virtual screening and combinatorial chemistry

Virtual screening in a huge collection of virtual combinatorial libraries has led to the identification of two new structural classes of GPR119 agonists with submicromolar in vitro potencies. Herein, we describe the virtual screening process involving feature trees fragment space searches followed by a 3D postprocessing step. The in silico findings were then filtered and prioritized, and finally, combinatorial libraries of target molecules were synthesized. Furthermore the so-called activity-anchor principle is introduced as an element to increase the chance to generate true hits. An activity anchor is a structural element expected to provide key contributions to a certain biological activity. Application of this technique has led to the discovery of two new GPR119-agonist hit series, one of which was further optimized to progress as a novel lead class.